Press Releases Archives Public Relations Contacts	Font Size:   December 12, 2006   ABILIFY® (aripiprazole) Injection for Intramuscular Use For Adults with Agitation Associated with Schizophrenia or Bipolar Mania Now Available   December 7, 2006   ABILIFY® (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults with Bipolar I Disorder Following Treatment For a Recent Manic or Mixed Episode   September 7, 2006   Helping Hands Grants Support Community Mental Health Programs, Funded by Otsuka America Pharmaceutical, Inc.   August 17, 2006   Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY® DISCMELT™ (aripiprazole)   May 30, 2006   American Psychiatric Foundation Announces Recipients of 2006 Awards for Advancing Minority Mental Health - Supported by a Grant from Otsuka America Pharmaceutical, Inc.   May 25, 2006   Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care in Management of Community-Treated Patients with Schizophrenia   May 16, 2006   ABILIFY® (aripiprazole) Demonstrated Efficacy as Maintenance Therapy in Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode   March 13, 2006   American Psychiatric Foundation Announces Recipients of Inaugural Helping Hands Grants -  Supported by a Grant by Otsuka America Pharmaceutical, Inc.   February 7, 2006   Bristol-Myers Squibb Company and Otsuka Pharmaceutical, Co., Ltd.  Announce Availability of 2mg (aripiprazole) Tablet and Nonrefrigerated Oral Solution   August 18, 2005   American Psychiatric Foundation’s Awards for Advancing Minority Mental Health Is Seeking Applicants for its 2005 Program   August 15, 2005   Otsuka Announces Support of Helping Hands Grant Program   June 1, 2005   Otsuka Celebrates 20 Successful Years In Maryland   May 25, 2005   New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia   May 18, 2005   Multiple Studies at DDW Report on Adacolumn® Apheresis Device in Treating Inflammatory Bowel Disease   April 26, 2005   Otsuka America Pharmaceutical, Inc. Launches National and Local Initiatives to Eliminate Minority Health Disparities   April 1, 2005   Hiromi Yoshikawa, Chairman and CEO of Otsuka America Pharmaceutical, Inc. Joins PhRMA Board of Directors   March 23, 2005   American Psychiatric Foundation Announces 2004 Recipients of Awards for Advancing Minority Mental Health   March 7, 2005   Abilify® (aripiprazole) Granted Approval for New Indication   January 4, 2005   FDA Provides Oral Solution Formulation of Abilify® (aripiprazole)   December 21, 2004   American Heart Association Presents Arteriosclerosis/Heart Failure Research Prize.   October 7, 2004   Otsuka America Pharmaceutical, Inc. Enters Co-Promotion Alliance with Santarus, Inc   October 1, 2004   FDA Approves Abilify® (aripiprazole) for Treatment of Acute Bipolar Mania, Including Manic and Mixed Episodes   September 21, 2004   Terry Prime Promoted to Vice President, Marketing of Otsuka America Pharmaceutical, Inc.   September 15, 2004   Otsuka America Pharmaceutical, Inc. Receives Frost & Sullivan’s 2004 Product Innovation of the Year Award for Antipsychotic Medications   August 10, 2004   Otsuka’s Adacolumn® Device to Enter Pivotal Study in Crohn’s Disease   May 18, 2004   Data Presented at Digestive Disease Week on Two Otsuka Products in Development for Inflammatory Bowel Disease   May 5, 2004   New Data and Analyses Demonstrate Abilify® (aripiprazole) Effective at Treating Patients with Acute Manic and Mixed Episodes of Bipolar Disorder   May 5, 2004   Clinical Study Shows Intramuscular Administration of Aripiprazole (Abilify®) Significantly Improves Acute Agitation in Patients with Schizophrenia   April 13, 2004   American Psychiatric Foundation Presents First-Ever Minority Mental Health Awards   April 7, 2004   Otsuka's Adacolumn® Device to Enter Pivotal Study in Ulcerative Colitis   November 14, 2003   Study Shows 40 Percent Relative Risk Reduction in Coronary Stent Blockage with Cilostazol Added to Standard Therapy   September 8, 2003   FDA Approveds Abilify ® (aripiprazole) Supplemental New Drug Application (sNDA for Maintaining Stability in Patients with Schizophrenia   July 16, 2003   Supplemental New Drug Application Submitted for Abilify (aripiprazole) for the Treatment of Acute Bipolar Mania   May 20, 2003   Results from New Clinical Studies: Aripiprazole Significantly Improved Symptoms of Acute Bipolar Mania   May 19, 2003   Aripiprazole Demonstrates Better Weight Change Profile, Comparable Efficacy in Schizophrenia Compared to Olanzapine in New Study   May 12, 2003   Otsuka Teams with American Psychiatric Foundation for New Minority Mental Health Awards Program   February 25, 2003   Supplemental New Drug Application (sNDA) for Long-Term Schizophrenia Treatment Submitted for Abilify (aripirprazole)
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989